ethinylestradiol Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
estrogens 1082 57-63-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethinylestradiol betadex
  • ethynyl estradiol
  • ethinylestradiol
  • ethinyl estradiol
  • 17-ethinylestradiol
  • ethinyloestradiol
A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.
  • Molecular weight: 296.41
  • Formula: C20H24O2
  • CLOGP: 3.68
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS: -4.64
  • ROTB: 0

Drug dosage:

DoseUnitRoute
25 mcg O
1.50 mg O

Approvals:

DateAgencyCompanyOrphan
June 25, 1943 FDA SCHERING

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary embolism 3450.37 51.89 866 4714 33560 4599852
Inappropriate schedule of product administration 3392.05 51.89 787 4793 21583 4611829
Device expulsion 3131.84 51.89 537 5043 2703 4630709
No adverse event 2633.93 51.89 642 4938 21521 4611891
Incorrect product administration duration 2000.04 51.89 379 5201 3548 4629864
Deep vein thrombosis 1903.28 51.89 511 5069 24983 4608429
Metrorrhagia 1680.45 51.89 302 5278 2028 4631384
Unintended pregnancy 1600.72 51.89 298 5282 2490 4630922
Product quality issue 1351.37 51.89 372 5208 19727 4613685
Pregnancy with contraceptive device 920.60 51.89 159 5421 807 4632605
Device breakage 819.79 51.89 164 5416 2038 4631374
Menorrhagia 788.22 51.89 174 5406 3568 4629844
Vaginal haemorrhage 576.89 51.89 144 5436 5085 4628327
Product storage error 530.51 51.89 157 5423 10592 4622820
Maternal exposure before pregnancy 513.62 51.89 98 5482 928 4632484
Medical device discomfort 498.99 51.89 84 5496 352 4633060
Migraine 476.37 51.89 153 5427 13556 4619856
Abnormal withdrawal bleeding 459.27 51.89 62 5518 12 4633400
Vaginal discharge 441.20 51.89 86 5494 919 4632493
Dysmenorrhoea 381.41 51.89 73 5507 702 4632710
Vulvovaginal discomfort 376.33 51.89 69 5511 513 4632899
Intentional medical device removal by patient 357.33 51.89 54 5526 88 4633324
Abortion induced 335.16 51.89 89 5491 4008 4629404
Menstruation delayed 334.90 51.89 59 5521 339 4633073
Menstruation irregular 329.00 51.89 74 5506 1642 4631770
Thrombosis 324.52 51.89 124 5456 18280 4615132
Medical device site discomfort 300.46 51.89 43 5537 35 4633377
Hypercoagulation 297.22 51.89 58 5522 622 4632790
Headache 287.25 51.89 213 5367 122160 4511252
Depression 283.17 51.89 150 5430 47583 4585829
Abortion spontaneous 254.99 51.89 97 5483 14095 4619317
Menstrual disorder 244.96 51.89 53 5527 975 4632437
Pulmonary infarction 244.45 51.89 51 5529 782 4632630
Anxiety 237.88 51.89 134 5446 47877 4585535
Vena cava filter insertion 228.29 51.89 35 5545 66 4633346
Cervical dysplasia 225.79 51.89 47 5533 712 4632700
Coagulopathy 218.46 51.89 70 5510 6110 4627302
Muscle spasms 217.23 51.89 114 5466 35376 4598036
Product shape issue 217.10 51.89 33 5547 57 4633355
Chest pain 212.61 51.89 127 5453 50573 4582839
Vulvovaginal mycotic infection 211.63 51.89 46 5534 865 4632547
Withdrawal bleed 207.67 51.89 30 5550 28 4633384
Cerebral venous sinus thrombosis 206.43 51.89 41 5539 484 4632928
Amenorrhoea 206.01 51.89 54 5526 2304 4631108
Pregnancy on contraceptive 199.75 51.89 37 5543 292 4633120
Chlamydial infection 184.65 51.89 32 5548 164 4633248
Pain in extremity 183.57 51.89 126 5454 63613 4569799
Smear cervix abnormal 173.77 51.89 33 5547 302 4633110
Cerebral venous thrombosis 170.58 51.89 37 5543 688 4632724
Poor quality product administered 170.23 51.89 43 5537 1580 4631832
Off label use 163.81 51.89 158 5422 128955 4504457
Fungal infection 163.19 51.89 60 5520 7909 4625503
Cerebrovascular accident 159.96 51.89 99 5481 41901 4591511
Ovarian cyst 155.61 51.89 42 5538 2005 4631407
Nausea 153.65 51.89 177 5403 177156 4456256
Adverse event 149.83 51.89 69 5511 16103 4617309
Product use in unapproved indication 137.10 51.89 75 5505 25198 4608214
Hypomenorrhoea 137.05 51.89 24 5556 132 4633280
Abdominal pain 134.55 51.89 102 5478 59922 4573490
Product colour issue 130.94 51.89 28 5552 485 4632927
Urinary tract infection 124.67 51.89 85 5495 42305 4591107
Exposure during pregnancy 123.62 51.89 77 5503 32894 4600518
Uterine leiomyoma 122.45 51.89 33 5547 1565 4631847
Back pain 122.31 51.89 90 5490 50509 4582903
Vaginal infection 118.58 51.89 29 5551 930 4632482
Complication associated with device 117.84 51.89 41 5539 4601 4628811
Thrombophlebitis superficial 116.70 51.89 30 5550 1182 4632230
Thrombectomy 115.80 51.89 20 5560 100 4633312
Vulvovaginal pain 115.28 51.89 25 5555 464 4632948
Ectopic pregnancy 113.61 51.89 27 5553 765 4632647
Gastrooesophageal reflux disease 108.82 51.89 54 5526 14839 4618573
Embolism venous 107.54 51.89 27 5553 966 4632446
Papilloma viral infection 105.34 51.89 23 5557 441 4632971
Discomfort 104.89 51.89 44 5536 8206 4625206
Dyspareunia 104.47 51.89 23 5557 459 4632953
Device failure 103.27 51.89 33 5547 2846 4630566
Hypertension 102.15 51.89 81 5499 50717 4582695
Female sterilisation 101.59 51.89 18 5562 107 4633305
Anticoagulation drug level below therapeutic 101.47 51.89 21 5559 308 4633104
Product administration error 101.38 51.89 43 5537 8241 4625171
Menstruation normal 101.25 51.89 16 5564 40 4633372
Vulvovaginal burning sensation 100.75 51.89 22 5558 422 4632990
Product use issue 97.68 51.89 60 5520 24976 4608436
Device difficult to use 96.79 51.89 27 5553 1457 4631955
Pulmonary mass 93.18 51.89 32 5548 3451 4629961
Pelvic pain 92.32 51.89 29 5551 2365 4631047
Weight increased 90.42 51.89 66 5514 36515 4596897
Product prescribing error 90.25 51.89 38 5542 7148 4626264
Cholecystectomy 89.63 51.89 28 5552 2242 4631170
Polycystic ovaries 89.42 51.89 18 5562 228 4633184
Iron deficiency anaemia 85.89 51.89 30 5550 3402 4630010
Accidental underdose 85.65 51.89 19 5561 393 4633019
Asthma 84.43 51.89 48 5532 17326 4616086
Pain 83.90 51.89 95 5485 92775 4540637
Vulvovaginal swelling 83.41 51.89 16 5564 155 4633257
Haemorrhage 79.22 51.89 53 5527 25509 4607903
Rhinitis allergic 79.04 51.89 22 5558 1177 4632235
Application site rash 78.54 51.89 21 5559 965 4632447
Dyspnoea 77.77 51.89 112 5468 138873 4494539
Product dose omission 75.38 51.89 77 5503 66885 4566527
Vulvovaginal candidiasis 74.91 51.89 17 5563 391 4633021
Caesarean section 74.33 51.89 30 5550 5068 4628344
Tonsillectomy 74.22 51.89 17 5563 408 4633004
Superior sagittal sinus thrombosis 73.51 51.89 16 5564 302 4633110
Hypoaesthesia 73.44 51.89 55 5525 31610 4601802
Antiphospholipid antibodies positive 72.79 51.89 15 5565 215 4633197
Abdominal pain lower 71.89 51.89 28 5552 4308 4629104
Mood swings 71.73 51.89 30 5550 5547 4627865
Swelling 71.66 51.89 49 5531 24433 4608979
Cerebral thrombosis 70.30 51.89 18 5562 697 4632715
Tricuspid valve incompetence 65.75 51.89 24 5556 3090 4630322
Product adhesion issue 65.32 51.89 21 5559 1844 4631568
Abortion 64.44 51.89 18 5562 975 4632437
Uterine dilation and curettage 64.38 51.89 14 5566 263 4633149
Polymenorrhoea 64.03 51.89 14 5566 270 4633142
Post thrombotic syndrome 63.91 51.89 13 5567 174 4633238
Emotional disorder 63.12 51.89 24 5556 3461 4629951
Leukocytosis 62.69 51.89 30 5550 7604 4625808
Breast pain 62.40 51.89 20 5560 1739 4631673
Pleuritic pain 61.53 51.89 18 5562 1152 4632260
Fatigue 61.37 51.89 103 5477 145463 4487949
Hyperlipidaemia 60.59 51.89 26 5554 5119 4628293
Bacterial vulvovaginitis 60.21 51.89 12 5568 144 4633268
Endometriosis 60.20 51.89 16 5564 718 4632694
Vitamin D deficiency 58.51 51.89 20 5560 2125 4631287
Transverse sinus thrombosis 58.36 51.89 12 5568 170 4633242
Venous stent insertion 58.33 51.89 9 5571 18 4633394
Muscle strain 58.02 51.89 19 5561 1769 4631643
Breast tenderness 57.60 51.89 16 5564 849 4632563
Dysfunctional uterine bleeding 57.06 51.89 12 5568 191 4633221
Pulmonary hypertension 56.51 51.89 29 5551 8534 4624878
Colposcopy 55.61 51.89 8 5572 7 4633405
Endometrial ablation 55.27 51.89 10 5570 68 4633344
Vitamin B12 deficiency 54.99 51.89 16 5564 1004 4632408
Oligomenorrhoea 54.57 51.89 12 5568 238 4633174
Product physical issue 54.18 51.89 18 5562 1753 4631659
Pulmonary artery stenosis 54.16 51.89 11 5569 146 4633266
Poor quality device used 53.90 51.89 14 5566 574 4632838
Varicose vein 53.77 51.89 16 5564 1086 4632326
Atelectasis 52.66 51.89 22 5558 4053 4629359
Bacterial vaginosis 52.60 51.89 11 5569 170 4633242
Cervicitis 52.59 51.89 10 5570 92 4633320

Pharmacologic Action:

SourceCodeDescription
ATC G03CA01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ESTROGENS
Natural and semisynthetic estrogens, plain
ATC L02AA03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONES AND RELATED AGENTS
Estrogens
ATC G03AA01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA04 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA06 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA07 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA08 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA09 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA10 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA11 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA12 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA13 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA15 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA16 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AB01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB02 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB04 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB06 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB07 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03AB09 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
CHEBI has role CHEBI:76988 xenoestrogen
MeSH PA D003270 Contraceptive Agents
MeSH PA D003271 Contraceptive Agents, Female
MeSH PA D000080066 Contraceptive Agents, Hormonal
MeSH PA D003278 Contraceptives, Oral, Hormonal
MeSH PA D004967 Estrogens
MeSH PA D006728 Hormones
MeSH PA D012102 Reproductive Control Agents
FDA EPC N0000175825 Estrogen
FDA MoA N0000000100 Estrogen Receptor Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Premenstrual dysphoric disorder indication 596004
Contraception indication 13197004
Atrophic vaginitis indication 52441000
Acne vulgaris indication 88616000
Postmenopausal osteoporosis indication 102447009
Menopausal flushing indication 198436008
Atrophic vulva indication 248861000 DOID:14275
Amenorrhea off-label use 14302001 DOID:13938
Female hypogonadism syndrome off-label use 16041008
Polycystic ovaries off-label use 69878008
Dysmenorrhea off-label use 266599000
Postcoital contraception off-label use 268463003
Abnormal uterine bleeding unrelated to menstrual cycle off-label use 312984006
Menorrhagia off-label use 386692008
Heart valve disorder contraindication 368009 DOID:4079
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Myocardial infarction contraindication 22298006 DOID:5844
Diplopia contraindication 24982008
Retinal hemorrhage contraindication 28998008
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Benign mammary dysplasia contraindication 57993004
Acute nephropathy contraindication 58574008
Obstructive hyperbilirubinemia contraindication 59848001
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Hypercalcemia contraindication 66931009 DOID:12678
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Uterine leiomyoma contraindication 95315005 DOID:13223
Neoplasm of prostate contraindication 126906006 DOID:10283
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Endometriosis contraindication 129103003
Bed-ridden contraindication 160685001
Liver function tests abnormal contraindication 166603001
Mammography abnormal contraindication 168750009
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of cervix contraindication 363354003 DOID:4362
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Diabetes with Vascular Disease Complication contraindication
Benign Hepatic Cell Adenoma contraindication
Breast Carcinoma in Males contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.13 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.03MG/24HR TWIRLA AGILE N204017 Feb. 14, 2020 RX SYSTEM TRANSDERMAL 8883196 Nov. 22, 2020 A TRANSDERMAL METHOD OF CONTRACEPTION
0.05MG PREVEN EMERGENCY CONTRACEPTIVE KIT TEVA BRANDED PHARM N020946 Sept. 1, 1998 DISCN TABLET ORAL 6156742 Dec. 5, 2020 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
0.03MG/24HR TWIRLA AGILE N204017 Feb. 14, 2020 RX SYSTEM TRANSDERMAL 7045145 March 14, 2021 A TRANSDERMAL METHOD OF CONTRACEPTION
0.02MG YAZ BAYER HLTHCARE N021676 March 16, 2006 RX TABLET ORAL 7163931 Dec. 20, 2021 PREVENTION OF PREGNANCY
0.02MG,N/A BEYAZ BAYER HLTHCARE N022532 Sept. 24, 2010 RX TABLET ORAL 7163931 March 3, 2022 PREVENTION OF PREGNANCY
0.03MG,N/A SAFYRAL BAYER HLTHCARE N022574 Dec. 16, 2010 RX TABLET ORAL 7163931 March 3, 2022 PREVENTION OF PREGNANCY
0.03MG,0.01MG SEASONIQUE TEVA BRANDED PHARM N021840 May 25, 2006 RX TABLET ORAL 7615545 June 15, 2023 PREVENTION OF PREGNANCY
0.02MG,0.1MG LOSEASONIQUE TEVA BRANDED PHARM N022262 Oct. 24, 2008 RX TABLET ORAL 7615545 June 15, 2023 PREVENTION OF PREGNANCY
0.03MG,0.01MG SEASONIQUE TEVA BRANDED PHARM N021840 May 25, 2006 RX TABLET ORAL 7320969 Jan. 30, 2024 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
None QUARTETTE TEVA BRANDED PHARM N204061 March 28, 2013 RX TABLET ORAL 8450299 Oct. 7, 2025 PREVENTION OF PREGNANCY
0.03MG,0.01MG SEASONIQUE TEVA BRANDED PHARM N021840 May 25, 2006 RX TABLET ORAL 7855190 Dec. 5, 2028 PREVENTION OF PREGNANCY
0.02MG,0.1MG LOSEASONIQUE TEVA BRANDED PHARM N022262 Oct. 24, 2008 RX TABLET ORAL 7855190 Dec. 5, 2028 PREVENTION OF PREGNANCY
0.01MG,0.01MG LO LOESTRIN FE APIL N022501 Oct. 21, 2010 RX TABLET ORAL 7704984 Feb. 2, 2029 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
0.01MG,0.01MG,N/A LO MINASTRIN FE APIL N204654 July 24, 2013 DISCN TABLET, CHEWABLE, TABLET ORAL 7704984 Feb. 2, 2029 PREVENTION OF PREGNANCY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.03MG/24HR TWIRLA AGILE N204017 Feb. 14, 2020 RX SYSTEM TRANSDERMAL Feb. 14, 2023 NEW PRODUCT
0.013MG/24HR ANNOVERA THERAPEUTICSMD INC N209627 Aug. 10, 2018 RX RING VAGINAL Aug. 10, 2023 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor AGONIST Kd 9.83 WOMBAT-PK CHEMBL
Mu-type opioid receptor GPCR Ki 4.96 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 4.93 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 7.54 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.02 DRUG MATRIX
Glucocorticoid receptor Nuclear hormone receptor Ki 6.11 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.35 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 4.73 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 4.98 DRUG MATRIX
Sex hormone-binding globulin Secreted Kd 6.81 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.69 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 4.68 CHEMBL
Estrogen receptor beta Nuclear hormone receptor IC50 8.09 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.66 CHEMBL
Androgen receptor Nuclear hormone receptor IC50 7.30 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 6.24 WOMBAT-PK
5-hydroxytryptamine receptor 4 GPCR Ki 5.88 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 5.25 DRUG MATRIX
Progesterone receptor Transcription factor Ki 6.86 DRUG MATRIX
Androgen receptor Transcription factor IC50 5.09 CHEMBL

External reference:

IDSource
D004997 MESH_DESCRIPTOR_UI
4018022 VUID
N0000146366 NUI
C0015011 UMLSCUI
D00554 KEGG_DRUG
423D2T571U UNII
437 INN_ID
15432003 SNOMEDCT_US
4124 RXNORM
126097006 SNOMEDCT_US
4698 MMSL
d00229 MMSL
4018022 VANDF
72166 MMSL
001286 NDDF
CHEBI:4903 CHEBI
CHEMBL691 ChEMBL_ID
DB00977 DRUGBANK_ID
3WF PDB_CHEM_ID
5991 PUBCHEM_CID
7071 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Taytulla HUMAN PRESCRIPTION DRUG LABEL 2 0023-5862 KIT 0.02 mg None NDA 18 sections
GENERESS Fe HUMAN PRESCRIPTION DRUG LABEL 3 0023-6030 KIT 0.03 mg ORAL NDA 19 sections
NuvaRing HUMAN PRESCRIPTION DRUG LABEL 2 0052-0273 INSERT, EXTENDED RELEASE 0.02 mg VAGINAL NDA 20 sections
Tri-Lo-Sprintec HUMAN PRESCRIPTION DRUG LABEL 6 0093-2140 KIT 0.03 mg None ANDA 18 sections
Tri-Lo-Sprintec HUMAN PRESCRIPTION DRUG LABEL 6 0093-2140 KIT 0.03 mg None ANDA 18 sections
Tri-Lo-Sprintec HUMAN PRESCRIPTION DRUG LABEL 6 0093-2140 KIT 0.03 mg None ANDA 18 sections
Jinteli HUMAN PRESCRIPTION DRUG LABEL 2 0093-3122 TABLET 5 ug ORAL ANDA 20 sections
Camrese HUMAN PRESCRIPTION DRUG LABEL 3 0093-3134 KIT 0.01 mg None NDA AUTHORIZED GENERIC 19 sections
Camrese HUMAN PRESCRIPTION DRUG LABEL 3 0093-3134 KIT 0.03 mg None NDA AUTHORIZED GENERIC 19 sections
Reclipsen HUMAN PRESCRIPTION DRUG LABEL 2 0093-3304 KIT 0.03 mg None ANDA 15 sections
Junel Fe HUMAN PRESCRIPTION DRUG LABEL 2 0093-5328 KIT 0.02 mg None ANDA 19 sections
Gianvi HUMAN PRESCRIPTION DRUG LABEL 2 0093-5423 KIT 0.02 mg None NDA authorized generic 20 sections
Rivelsa HUMAN PRESCRIPTION DRUG LABEL 7 0093-6031 KIT 0.03 mg None NDA AUTHORIZED GENERIC 19 sections
Rivelsa HUMAN PRESCRIPTION DRUG LABEL 7 0093-6031 KIT 0.01 mg None NDA AUTHORIZED GENERIC 19 sections
Rivelsa HUMAN PRESCRIPTION DRUG LABEL 7 0093-6031 KIT 0.02 mg None NDA AUTHORIZED GENERIC 19 sections
Rivelsa HUMAN PRESCRIPTION DRUG LABEL 7 0093-6031 KIT 0.03 mg None NDA AUTHORIZED GENERIC 19 sections
camrese Lo HUMAN PRESCRIPTION DRUG LABEL 3 0093-6148 KIT 0.02 mg None NDA AUTHORIZED GENERIC 19 sections
camrese Lo HUMAN PRESCRIPTION DRUG LABEL 3 0093-6148 KIT 0.01 mg None NDA AUTHORIZED GENERIC 19 sections
Kelnor 1/50 HUMAN PRESCRIPTION DRUG LABEL 2 0093-8073 KIT 50 ug None ANDA 15 sections
Previfem HUMAN PRESCRIPTION DRUG LABEL 2 0254-2029 KIT 0.04 mg None ANDA 18 sections
Tri-Previfem HUMAN PRESCRIPTION DRUG LABEL 6 0254-2030 KIT 0.04 mg None ANDA 20 sections
Tri-Previfem HUMAN PRESCRIPTION DRUG LABEL 6 0254-2030 KIT 0.04 mg None ANDA 20 sections
Tri-Previfem HUMAN PRESCRIPTION DRUG LABEL 6 0254-2030 KIT 0.04 mg None ANDA 20 sections
Orsythia HUMAN PRESCRIPTION DRUG LABEL 2 0254-2032 KIT 0.02 mg None ANDA 13 sections
EMOQUETTE HUMAN PRESCRIPTION DRUG LABEL 2 0254-2033 KIT 0.03 mg None ANDA 16 sections
XULANE HUMAN PRESCRIPTION DRUG LABEL 2 0378-3340 PATCH 35 ug TRANSDERMAL ANDA 19 sections
LEVONORGESTREL AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-6550 KIT 30 ug None ANDA 14 sections
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-7274 TABLET 0.03 mg ORAL ANDA 14 sections
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-7280 TABLET 0.02 mg ORAL ANDA 14 sections
LEVONORGESTREL AND ETHINYL ESTRADIOL HUMAN PRESCRIPTION DRUG LABEL 2 0378-7281 KIT 0.03 mg None ANDA 19 sections